Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months

Area of Science:

• Ophthalmology
• Medical Imaging
• Pharmacology

Background:

• Geographic atrophy (GA) is a leading cause of vision loss.
• Spectral-domain optical coherence tomography (SD-OCT) is crucial for GA imaging.
• Automated quantitative OCT analysis can enhance GA diagnosis and monitoring.

Purpose of the Study:

• To analyze the association between pegcetacoplan and consensus GA SD-OCT endpoints.
• To evaluate the efficacy of pegcetacoplan in reducing GA growth using SD-OCT.

Main Methods:

• Post hoc analysis of 11,614 SD-OCT volumes from 936 participants in the OAKS and DERBY phase 3 trials.
• Participants received monthly or every-other-month pegcetacoplan or sham injections for 24 months.
• Primary endpoint: change in retinal pigment epithelium and outer retinal atrophy area using SD-OCT, analyzed by ETDRS regions.

Main Results:

• Pegcetacoplan treatment was associated with reduced GA growth rates compared to sham treatment over 24 months.
• Reductions in atrophy area were significant at all time points from 3 to 24 months.
• Monthly pegcetacoplan showed a trend towards greater reduction than every-other-month dosing, particularly in parafoveal and perifoveal regions.

Conclusions:

• Pegcetacoplan treatment is associated with reduced growth of geographic atrophy.
• Findings provide insight into pegcetacoplan's effects on retinal pigment epithelium and photoreceptors in GA.
• Quantitative SD-OCT analysis supports pegcetacoplan's role in managing GA.